{"id":"NCT00232596","sponsor":"GlaxoSmithKline","briefTitle":"Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2005-10-04","resultsPosted":"2011-10-25","lastUpdate":"2016-12-08"},"enrollment":306,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Seizures"],"interventions":[{"type":"DRUG","name":"Retigabine","otherNames":["D-23129","GKE-841"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Retigabine","type":"EXPERIMENTAL"}],"summary":"This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 1200 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).","primaryOutcome":{"measure":"Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)","timeFrame":"Baseline (Week -7 through Week 0), Week 1 through Week 18","effectByArm":[{"arm":"Placebo - DB Phase (Titration + Maintenance)","deltaMin":-17.5,"sd":null},{"arm":"Retigabine - DB Phase (Titration + Maintenance)","deltaMin":-44.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":54,"countries":["United States","Argentina","Brazil","Canada","Mexico"]},"refs":{"pmids":["22512894"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":152},"commonTop":["Dizziness","Somnolence","Headache","Fatigue","Urinary tract infection"]}}